Bestudering van de post-mortale verdeling van geneesmiddelen.
Bestudering van de post-mortale verdeling van geneesmiddelen.
OSIBOOST 2 is a clinical trial designed to enhance the cost-effectiveness of Osimertinib for patients with Non-Small Cell Lung Cancer (NSCLC). Although Osimertinib significantly improves progression-free survival compared to older EGFRm-targeted therapies, its high cost remains a concern. To address this, the trial investigates the use of the CYP3A4 inhibitor Cobicistat, which reduces the metabolism of Osimertinib and increases its exposure (a process known as pharmacokinetic boosting). This approach allows patients to take a lower dose of Osimertinib while achieving the same therapeutic effect, potentially making the treatment more affordable without compromising its efficacy.
To demonstrate abnormalities in antibiotic pharmacokinetics and consequently antibiotic exposure in critically ill patients
All people living with HIV need life-long treatment with antiretroviral therapy (ART). However, ART coverage in children living with HIV continues to lag behind adults and many paediatric patients in sub-Saharan Africa still do not receive optimal paediatric treatment formulations or state-of-the-art drugs. Studies of efficacy and safety of these drugs in children have lagged behind, and the full range of appropriate formulations to treat younger children are yet to be developed for both first- and second-line treatments.
Het optimaliseren van de antivirale behandeling van kinderen met HIV in Afrika door verdieping in de PK/PD van deze middelen, nieuwe formuleringen en het voorspellen van de PK middels modelleren.